Category: 137076-54-1

Chemistry is traditionally divided into organic and inorganic chemistry. name: 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid. The former is the study of compounds containing at least one carbon-hydrogen bonds.In a patent£¬Which mentioned a new discovery about 137076-54-1

Site-Specific 89Zr- And 111In-Radiolabeling and in Vivo Evaluation of Glycan-free Antibodies by Azide-Alkyne Cycloaddition with a Non-natural Amino Acid

Antibody-drug conjugates (ADCs) are a class of targeted therapeutics consisting of a monoclonal antibody coupled to a cytotoxic payload. Various bioconjugation methods for producing site-specific ADCs have been reported recently, in efforts to improve immunoreactivity and pharmacokinetics and minimize batch variance – potential issues associated with first-generation ADCs prepared via stochastic peptide coupling of lysines or reduced cysteines. Recently, cell-free protein synthesis of antibodies incorporating para-azidomethyl phenylalanine (pAMF) at specific locations within the protein sequence has emerged as a means to generate antibody-drug conjugates with strictly defined drug-antibody-ratio, leading to ADCs with markedly improved stability, activity, and specificity. The incorporation of pAMF enables the conjugation of payloads functionalized for strain-promoted azide-alkyne cycloaddition. Here, we introduce two dibenzylcyclooctyne-functionalized bifunctional chelators that enable the incorporation of radioisotopes for positron emission tomography with 89Zr (t1/2 = 78.4 h, beta+ = 395 keV (22%), gamma= 897 keV) or single photon emission computed tomography with 111In (t1/2 = 67.3 h, gamma= 171 keV (91%), 245 keV (94%)) under physiologically compatible conditions. We show that the corresponding radiolabeled conjugates with site-specifically functionalized antibodies targeting HER2 are amenable to targeted molecular imaging of HER2+ expressing tumor xenografts in mice and exhibit a favorable biodistribution profile in comparison with conventional, glycosylated antibody conjugates generated by stochastic bioconjugation.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.name: 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid, you can also check out more blogs about137076-54-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.137076-54-1, Name is 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid, molecular formula is C28H52N4O8. In a article£¬once mentioned of 137076-54-1

Toward development of targeted nonsteroidal antiandrogen-1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid-gadolinium complex for prostate cancer diagnostics

Androgen receptors are present in most advanced prostate cancer specimens, having a critical role in development of this type of cancer. For correct prognosis of patient conditions and treatment monitoring, noninvasive imaging techniques have great advantages over surgical procedures. We developed synthetic methodologies for preparation of novel androgen receptor-targeting agents in an attempt to build a versatile platform for prostate cancer imaging and treatment. The structure of these compounds comprises of a lanthanoid metal ion, gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (Gd-DOTA)-based binding fragment and, connected to it by a flexible linker, bicalutamide-derived nonsteroidal antiandrogen moiety. A representative gadolinium complex 15 was evaluated as a magnetic resonance imaging (MRI) agent in C57/bl6 male mouse bearing orthotopic TRAMP C2 prostate tumor.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 137076-54-1, and how the biochemistry of the body works.137076-54-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 137076-54-1, Name is 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid. In a document type is Article, introducing its new discovery., 137076-54-1

Methoxinine ? an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates

Radiolabelled peptides with high specificity and affinity towards receptors that are overexpressed by tumour cells are used in nuclear medicine for the diagnosis (imaging) and therapy of cancer. In some cases, the sequences of peptides under investigations contain methionine (Met), an amino acid prone to oxidation during radiolabelling procedures. The formation of oxidative side products can affect the purity of the final radiopharmaceutical product and/or impair its specificity and affinity towards the corresponding receptor. The replacement of Met with oxidation resistant amino acid analogues, for example, norleucine (Nle), can provide a solution. While this approach has been applied successfully to different radiolabelled peptides, a Met ? Nle switch only preserves the length of the amino acid side chain important for hydrophobic interactions but not its hydrogen-bonding properties. We report here the use of methoxinine (Mox), a non-canonical amino acid that resembles more closely the electronic properties of Met in comparison to Nle. Specifically, we replaced Met15 by Mox15 and Nle15 in the binding sequence of a radiometal-labelled human gastrin derivative [d-Glu10]HG(10-17), named MG11 (d-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2). A comparison of the physicochemical properties of 177Lu-DOTA[X15]MG11 (X = Met, Nle, Mox) in vitro (cell internalization/externalization properties, receptor affinity (IC50), blood plasma stability and logD) showed that Mox indeed represents a suitable, oxidation-stable amino acid substitute of Met in radiolabelled peptide conjugates. Copyright

Interested yet? Keep reading other articles of 142128-92-5!, 137076-54-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of DOTA tri-t-butyl ester (10 mg, 0.017 mmol), HBTU (7.8 mg, 0.021 mmol) and DIEA (6.0 muL, 0.034 mmol) in anhydrous DMF (0.5 mL) was stirred at room temperature under nitrogen for 20 minutes, and treated with the product of Part A (8.7 mg, 0.017 mmol). Stirring was continued for 1 hour and the solution was concentrated under reduced pressure. The residue was dissolved in TFA (1 mL), treated with TIS (10 muL), and stirred for 4 hours. The solution was concentrated under reduced pressure and the residue was purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.9%/min gradient of 0 to 18% acetonitrile containing 0.1% TFA at a flow rate of 20 mL/min. The main EPO product peak eluting at 20.5 minutes was lyophilized to give the title compound as a colorless solid (8.5 mg, 62%, HPLC purity 96%). MS (ESI): 793.5 (40, M+H), 396.9 (100, M+2H); HRMS: Calcd for C37H62N9O10 (M+H): 792.4620; Found: 792.462

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

To a solution of 2 (194 mg, 0.09 mmol) and 3 ( 52mg, 0.09ml) in acetonitrile (8ml), HTBU ( 34mg, 0.09 mmol) wa added followed by triethylamine ( 25 muL, 0.18mmol) at RT. the reaction was stirred for 18 h. The reaction was diluted with 30 mL dichloromethane and washed 0.1 N HCl(30 mL), 10% NaHCO3 (30 mL), brine (30 mL), then dried over MgSO4, and concentrated. The crudeproduct was purified by column chromatography (DCM:MeOH = 97:5 DCM:MeOH = 85:15) togive 4 (Figure 7) as a foam (105 mg, 43%). 1H-NMR (400 MHz, CDCl3): delta 3.68-3.47 (m, 104H,CH2OCH2CH2OCH2CH2OCH2, C3N3-NHCH2CH2CH2O , Dota-CONHCH2CH2CH2O), 3.22-3.18(br m, 8H, BocNHCH2), 1.84-1.72 (m, 28H, OCH2CH2CH2), 1.46 (s, 9H), 1.45 (s, 9H), 1.42 (s, 45H);13C-NMR (100 MHz, CDCl3) delta 176.6 (DOTA-OCOtBu), 174.4 (DOTA-OCOtBu), 172.3 (DOTA-OCOtBu),not found (C3N3), 156.0 (NHCOtBu), 81.7 (DOTA-OC(CH3)3), 78.7 (C(CH3)3), 70.47 (OCH2CH2O),70.21 (OCH2CH2O), 70.17 (OCH2CH2O), 70.10 (OCH2CH2O), 69.42 (CH2CH2CH2O), 69.02(CH2CH2CH2O), 57.5 (DOTA), 56.2 (DOTA), 55.6 (DOTA), 53.5 (DOTA), 41.9 (NH2CH2CH2CH2O),38.5 (CH2CH2CH2O), 38.4 (CH2CH2CH2O), 29.6 (NH2CH2CH2CH2O), 29.3 (NH2CH2CH2CH2O),28.4 (C(CH3)3), 27.94 (DOTA-OC(CH3)3), 27.87 (DOTA-OC(CH3)3); MS (ESI-TOF) calcd. forC127H242N27O36 2721.7936, found 2721.8117 [M + H]+. Spectra appear in the Supplementary Materials:Figures S11-S13

137076-54-1, As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Article; Lee, Changsuk; Ji, Kun; Simanek, Eric E.; Molecules; vol. 21; 3; (2016);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

A solution of the product of Example 3OB (30.0 mg, 63.8 mumol) and /-Pr2NEt (11 muL, 63 mumol) in dry DMF (1.00 mL) was transferred to a previously prepared solution of (4,7, 10-tris-f¡ãrt-butoxycarbonylmethyl- 1 ,4,7, 10-tetraazacyclododec- 1 – yl)acetic acid (47.5 mg, 82.9 mumol) in DMF (3.00 mL) containing HBTU (26.6 mg, 70.1 mumol), HOBt (10.7 mg, 69.9 mumol) and /-Pr2NEt (44 muL, 0.25 mmol); additional DMF (2 x 0.50 mL) was used to quantitate the transfer. The resulting solution was maintained at 22 C for 3 hours, then concentrated in vacuo and the residue treated with a solution OfEt3SiH in TFA (9:1 v/v, 3.30 mL). After stirring 2.5 hours at 22 0C, the resulting solution was concentrated in vacuo and purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.67%/min gradient of 0- 20% acetonitrile containing 0.1% TFA at a flow rate of 20 rnL/min. The main product peak eluting at 5.5 minutes was lyophilized to a white solid (65.0 mg, 53.6 mumol; 84.0%). MS (ESI): 643.3 (65.2, M+H), 530.3 (36.0), 322.3 (100, M+2H), 265.7 (49.7). HRMS: Calcd for C28H51N8O9: 643.3774; found: 643.3763. The optical purity of the product was established by chiral GLC analysis; 99.8% D- leucine.

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 6.1 Preparation of compounds 30a-b- General Procedure: HBTU (1 eq) and DIPEA (1.7 eq) were sequentially added to a suspension ofcompound 26 in CH2CI2 (concentration 1% w/v) and the mixture was keptunder stirring at room temperature for 30 min; phosphoethanolamine (DLPEn = 10 or DMPE n = 12) (1 eq) was then added and the mixture was maintained under stirring at room temperature for 24 h. The reactionmixture was sequentially washed with H20 (100 mL), acidified H20 (pH 4-5with HCI; 100 mL) and H20 (100 mL). The organic layer was dried(Na2S04), filtered and evaporated, and the so-obtained crude material waspurified by flash chromatography to obtain compounds 30a-b. Example 6.1a Preparation of 10-[(10R)-7-hydroxy-7-oxido-2,13-dioxo-10-[(1-oxododecyl)oxy]-6,8,12-trioxa-3-aza-7-phosphatetracos-1-yl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid tris [(1,1-dimethyl)ethyl] ester 30aReagents: Compound 26 (968 mg; 1.69 mmol); 1,2-didodecanoyl-sn-glycero-3-phosphoethanolamine (980 mg; 1.69 mmol).Compound 30a (605 mg, 0.53 mmol); Yield 32%.Analytical dataHPLC-ELSD: 40.6% (area%)Mr: 1134.48 (C57H 108N5015P) 1H-and 13C-NMR and MS are compatible with the structure.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BRACCO IMAGING SPA; GHIANI, Simona; MAIOCCHI, Alessandro; BRIOSCHI, Chiara; VISIGALLI, Massimo; CABELLA, Claudia; MIRAGOLI, Luigi; WO2014/37498; (2014); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 4- Synthesis of tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate To a solution of product 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (572.7 mg, 1 mmol) in dry DMF (15 mL), amino-maleimide 137 (483.3 mg, 1 mmol) was added with HATU (272 mg, 1.4 mmol) and DIPEA (360 muL, 1.84 mmol). The mixture was stirred overnight at room temperature. After removing the solvent under the vacuum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 90:10) to give compound tri-tert-butyl 2,2′,2′-(10-(2-((2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (396 mg, 57 %). Rf : 0.3 (CH2Cl2/MeOH, 90:10). 1H NMR (300MHz, CDCl3) delta 8.30 (b, 1H, NH), 6.86 (s,2H, H6′), 3.78-3.54 (br, 4H, H3′, H4′), 3.54 (br, 4H, H13, H1′), 3.48 (br, 4H, H8), 3.09-2.99 (m, 8H, H2, H3), 2.97-2.86 (m, 8H, H5, H6), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 171.6 (C2′), 171.0 (C5′), 170.4 (C9, C14), 134.2 (C6′), 81.5 (C16), 81.3 (C11), 57.8 (C1′), 55.7-55.2 (C8, C13), 54.1-51.5 (C2, C3), 51.0-48.9 (C5, C6), 38.0 (C4′), 32.7 (C3′), 27.8 (C17), 27.6 (C12). MS (ESI) : m/z 695 [M + H]+.

137076-54-1, 137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Institut Curie; Centre National de la Recherche Scientifique; The designation of the inventor has not yet been filed; EP2740491; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

solution of DOTA tri-t-butyl ester (0.972 g, 1.70 mmol), HBTU (0.772 g, 2.04 mmol), HOBt (0.312 g, 2.04 mmol), and DIEA (0.59 niL, 5.9 mmol) in anhydrous DMF (8.0 mL) was stirred at room temperature under nitrogen for 20 minutes. The product of Part B (1.38 g, 1.70 mmol) was added in one portion. Additional HBTU (0.772 g, 2.04 mmol) was added after 1 hour and the reaction was stirred for an additional 3 hours. The reaction mixture was quenched with 10% citric acid (20 mL) and diluted with dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (3 x 30 mL). The combined organic extracts were washed consecutively with 10% citric acid (30 mL), saturated NaHCO3 (3 x 30 mL), and saturated NaCl (3 x 30 mL), dried (MgSO4), filtered, and concentrated to give a yellow oil. The oil was purified by flash chromatography over silica gel, eluting with ethyl acetate to give the title compound as a colorless oil (0.746 g, 48%). 1H NMR (4:1 CDCl3:DMSO-<4): delta 7.54 (m, 2H), 7.41 (m, 2H), 7.17 (m, 2H), 7.08 (m, 2H), 4.15 (d, 2H), 4.02 (m, IH), 2.97 (m, 2H), 2.68-2.45 (m, 24H), 2.00 (t, 2H), 1.44 (t, 2H), 1.30-1.11 (m, 31H). MS (ESI): 461.9 (100, M+2H), 922.5 (80, M+H)., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

Example 7-Synthesis of tri-tert-butyl 2,2′,2′-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate The procedure that was followed was described in . Compound 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid (400 mg, 0.70 mmol), N-hydroxysuccinimide (90.4 mg, 0.78 mmol, 1.1 equiv.), and Obenzotriazol- 1-yl-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) (296 mg, 0.78 mmol, 1.1 equiv.) were dissolved in 10 mL of acetonitrile. The reaction was stirred at room temperature for 24 hr. After removing the solvent under vaccum, the crude product was purified by flash chromatography on silica gel (CH2Cl2/MeOH, 85:15) to give compound tri-tert-butyl 2,2′,2′-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate as a white foam (404 mg, 86 %). Rf : 0.3 (CH2Cl2/MeOH, 85:15). 1H NMR (300MHz, CDCl3) delta 3.51 (br, 4H, H8), 3.54 (br, 4H, H13, H1′), 3.32-3.26 (m, 4H, H6), 3.08-2.99 (m, 4H, H5), 2.97-2.86 (m, 8H, H2, H3), 2.85 (s, H4′), 1.46 (s, 18H, H12), 1.45 (s, 9H, H17). 13C NMR (75MHz, CDCl3) delta 173.4 (C9, C14), 173.1 (C2′), 169.9 (C3′), 82.6 (C16), 82.4 (C11), 55.8 (C8), 55.7 (C13), 54.2 (C1′), 54.1-51.5 (C2, C3), 51.0-48.9 (C5, C6), 27.8 (C17), 27.6 (C12). 25.6 (C4′) MS (Cl/NH3) m/z 692 [M + H]+, 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; Institut Curie; Centre National de la Recherche Scientifique; The designation of the inventor has not yet been filed; EP2740491; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI